# Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002)

> **NCT01324440** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 64 (actual)

## Conditions studied

- Staphylococcal Infections

## Interventions

- **BIOLOGICAL:** V710 (30 µg) with MAA
- **BIOLOGICAL:** V710 (30 µg) without MAA

## Key facts

- **NCT ID:** NCT01324440
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2015-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01324440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01324440, "Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01324440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*